- Trials with a EudraCT protocol (11)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
11 result(s) found for: Homicidal ideation.
Displaying page 1 of 1.
EudraCT Number: 2016-001556-21 | Sponsor Protocol Number: SEP361-202 | Start Date*: 2016-10-27 | |||||||||||
Sponsor Name:SUNOVION PHARMACEUTICALS INC. | |||||||||||||
Full Title: A 26-Week Open-label Safety and Tolerability Extension Study of SEP-363856 in Adult Subjects with Schizophrenia | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004383-23 | Sponsor Protocol Number: RISSCH4055 | Start Date*: 2005-11-24 |
Sponsor Name:Janssen Cilag Ltd | ||
Full Title: Pragmatic randomized trial of Risperdal Consta versus oral atypical antipsychotics in poorly adherent subjects with schizophrenia ina routine care setting. Protocol RISSCH4055; Phase IV (risperid... | ||
Medical condition: Schizophrenia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) IE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2004-000870-29 | Sponsor Protocol Number: RISSCH3001 | Start Date*: 2004-11-04 |
Sponsor Name:Janssen-Cilag Medical Affairs EMEA | ||
Full Title: CONSTATRE Risperdal Consta Trial of Relapse Prevention and Effectiveness | ||
Medical condition: SCHIZOPHRENIA, SCHIZOAFFECTIVE DISORDER | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: HU (Completed) ES (Completed) AT (Completed) SE (Completed) CZ (Completed) LV (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-001711-31 | Sponsor Protocol Number: D1050238 | Start Date*: 2012-02-29 | |||||||||||
Sponsor Name:Sunovion Pharmaceuticals Inc. | |||||||||||||
Full Title: A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance treatment of subjects with schizophrenia | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014811-11 | Sponsor Protocol Number: R076477PSZ3003 | Start Date*: 2010-01-25 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: Estudio multicéntrico, aleatorizado, doble ciego, controlado, de dosis flexibles y grupos paralelos para evaluar la eficacia y seguridad de paliperidona de liberación prolongada en el tratamiento d... | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) CZ (Completed) SK (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002048-29 | Sponsor Protocol Number: RGH-MD-06 | Start Date*: 2012-03-29 | |||||||||||
Sponsor Name:Forest Research Institute, Inc | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, parallel-group study of cariprazine (RGH-188) in the prevention of relapse in patients with schizophrenia | |||||||||||||
Medical condition: schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002068-30 | Sponsor Protocol Number: ITI-007-304 | Start Date*: 2021-12-16 | |||||||||||
Sponsor Name:Intra-Cellular Therapies, Inc. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel- group Study of Lumateperone for the Prevention of Relapse in Patients with Schizophrenia | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022914-15 | Sponsor Protocol Number: A3051123 | Start Date*: 2012-03-01 | |||||||||||
Sponsor Name:Pfizer, S.L.U. | |||||||||||||
Full Title: A PHASE 4, RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO -CONTROLLED, MULTICENTER STUDY EVALUATING THE NEUROPSYCHIATRIC SAFETY AND EFFICACY OF 12 WEEKS VARENICLINE TARTRATE 1MG BID AND BUPROPION HYD... | |||||||||||||
Medical condition: Nicotine Addiction with the desire to quit smoking | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) DK (Completed) FI (Completed) BG (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004532-30 | Sponsor Protocol Number: R092670PSY3016 | Start Date*: 2019-08-09 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: Single-arm, Open-label Extension to a Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000577-38 | Sponsor Protocol Number: PSZ-3002 | Start Date*: 2007-08-16 | |||||||||||
Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium | |||||||||||||
Full Title: A 2-Year, Open-Label, Single-Arm Safety Study of Flexibly Dosed Paliperidone Extended Release (1.5-12 mg/day) in the Treatment of Adolescents (12 to 17 Years of Age) with Schizophrenia | |||||||||||||
Medical condition: Adolescents Schizphrenia | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) BE (Completed) EE (Completed) PL (Completed) BG (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002247-16 | Sponsor Protocol Number: R092670SCH3005 | Start Date*: 2010-03-10 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmit... | |||||||||||||
Medical condition: Recently diagnosed (1-5 years since diagnosis) schizophrenia. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) DE (Completed) HU (Completed) ES (Completed) LT (Completed) BE (Completed) FR (Completed) EE (Completed) IT (Completed) BG (Completed) AT (Completed) GB (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
